Nature medicine · 2015
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
СтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПоддержка правительства СШАВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ortega-Molina Ana, Boss Isaac W, Canela Andres, Pan Heng, Jiang Yanwen, Zhao Chunying, Jiang Man, Hu Deqing, Agirre Xabier, Niesvizky Itamar, Lee Ji-Eun, Chen Hua-Tang, Ennishi Daisuke, Scott David W, Mottok Anja, Hother Christoffer, Liu Shichong, Cao Xing-Jun, Tam Wayne, Shaknovich Rita, Garcia Benjamin A, Gascoyne Randy D, Ge Kai, Shilatifard Ali, Elemento Olivier, Nussenzweig Andre, Melnick Ari M, Wendel Hans-Guido
Аннотация
The gene encoding the lysine-specific histone methyltransferase KMT2D has emerged as one of the most frequently mutated genes in follicular lymphoma and diffuse large B cell lymphoma; however, the biological consequences of KMT2D mutations on lymphoma development are not known. Here we show that KMT2D functions as a bona fide tumor suppressor and that its genetic ablation in B cells promotes lymphoma development in mice. KMT2D deficiency also delays germinal center involution and impedes B cell differentiation and class switch recombination. Integrative genomic analyses indicate that KMT2D affects methylation of lysine 4 on histone H3 (H3K4) and expression of a set of genes, including those in the CD40, JAK-STAT, Toll-like receptor and B cell receptor signaling pathways. Notably, other KMT2D target genes include frequently mutated tumor suppressor genes such as TNFAIP3, SOCS3 and TNFRSF14. Therefore, KMT2D mutations may promote malignant outgrowth by perturbing the expression of tumor suppressor genes that control B cell-activating pathways.